Sorbent Gets $36 Million To Fund Phase II Program In Congestive Heart Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
With input from new investor Novartis Venture Fund, the biotech will move its lead compound from chronic kidney disease into the potentially more lucrative heart failure space.
You may also be interested in...
Sorbent Seeks A New Path To CV Therapy With Polymeric Drugs
Company is trying to raise $30 million to fund a Phase IIb program for lead candidate in ESRD, plus bring a second compound into the clinic.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.